Effect Of GW501516X On How The Heart Obtains And Uses Energy

Stopped early

Conditions studied: Dyslipidaemias, Heart Failure

In brief

The purpose of this study is to determine the effect of a 4-week treatment period with GW501516X on how the heart obtains and uses energy. The energy of the heart will be measured by Magnetic Resonance Imaging (MRI). This study will also measure a number of other potential markers of drug activity, including levels of certain lipids (fats) and proteins in your blood. The data from this study may help researchers better understand the actions of this drug in the body and if this drug may be useful to treat patients with heart disease.

Key facts

Study ID

NCT00318617

Run by

GlaxoSmithKline

People needed

30

Starts

2005-12-01

Last updated by the study team

2012-03-19

Who can join

Age: 18 and older, up to 40. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Non-smoking.
• Body Mass Index of greater than 27 and less than 32 and who weigh 120 kg (264 lbs) or less and have a waist circumference of greater than 95 cm (37.5 inches).

You may not qualify if…

• History of muscle disease, coagulation disorders, heart disease or abnormal heart rhythm (or a family history of early coronary artery disease).
• Documented diabetes, hypoglycemia, thyroid disfunction or adrenal disorder.

Where it is running

• GSK Investigational Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.